Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.64 -1.12%
Revenue Growth %: -15.8%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -15.8%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), versus ($0.05) reported last year. Revenue for the quarter came in at $1.77 million, versus $1.34 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Monolithic Power Systems (MPWR) Reiterated at Buy by Stifel on Reaching $4B Target
- DA Davidson Reiterates Buy Rating on EVI Industries Inc. (EVI) Following Q4 Results
- Designer Brands Inc. (DBI) Tops Q2 EPS by 8c, Misses on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
